Fibrinolysis inhibition

The development of anti-fibrinolytic compounds to control hemorrhage due to excessive fibrinolytic activity has assumed more importance because of the increasing use of fibrinolytic therapy. A side effect of theraypy with the protein activators SK and UK is destruction of plasma fibrinogen which causes hemorrhage. The subject of fibrinolysis inhibition has been reviewed by Baumgeurten and Maxwell ... 

Schreiber A, Kaplan A, Austen K Inhibition by 62 ClINH of Hageman factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973 52 1402-1409. 

Familial lipoprotein(a) excess Lp(a) consists of 1 mol of LDL attached to 1 mol of apo(a). Apo(a) shows structural homologies to plasminogen. Premature coronary heart disease due to atherosclerosis, plus thrombosis due to inhibition of fibrinolysis. 

Plasminogen activator inhibitors have been shown to be present in a large variety of different cells and tissues. These inhibitors are thought to play an important role in regulating tissue fibrinolysis. One of these inhibitors has been purified from cultured bovine aortic epithelial cells. This inhibitor has been shown to be a serine protease inhibitor and inhibits the function of two proteolytic enzymes urokinase and tissue plasminogen activator, both of which cleave and activate plasminogen. The mechanism by which this inhibitor functions is very similar to that described above with a-l-PI. Thus, the inhibitor forms a binary complex with the proteolytic enzyme and thereby inhibits its activity. Again in a situation comparable to that with a-l-PI, it was found that when the purified bovine aortic epithelial inhibitor was exposed to Al-chlorosuccinimide,... 

The inflammatory process in sepsis is linked to the coagulation system. Pro-inflammatory mediators maybe procoagulant and antifibrinolytic, whereas anti-inflammatory mediators may be fibrinolytic. A key factor in the inflammation of sepsis is activated protein C, which enhances fibrinolysis and inhibits inflammation. Protein C levels are decreased in septic patients. 

Fig. 14.1. The Thl/Th2 balance is central to the regulation of normal wound repair. Tissue injury results in the initiation of an inflammatory response, mediated by a variety of cells and their by-products. Immune cells are recruited and cross-regulate the Thl/ Th2 balance that occurs in response to the cytokine environment. This balance is in turn cross-regulated by the chemokine/chemokine-receptor expression profile, which functions to amplify the inflammatory process. Cells residing in the injured tissue release profibrotic mediators, which promote fibroblast activation, proliferation, and differentiation to the myofibroblast phenotype. Myofibroblasts produce collagen to repair damaged tissue, which is an event that is favored by the inhibition of MMP activity. The Thl/Th2 balance is central to whether a normal or aberrant wound-repair process is established A Thl environment promotes normal tissue resolution (fibrinolysis), whereas a Th2 environment maintains the progression of fibrotic disease (excessive collagen deposition).

The antithrombotic factors produced by endothelial cells are thrombomodulin (TM) and protein S (PS), components of the vitamin K-dependent protein C (PC) anticoagulant pathway, inhibiting F-Va-F-Villa (E15) tissue plasminogen activator (tPA), responsible for fibrinolysis (N2, LI8) and the lipoprotein-associated coagulation inhibitor (LACI), which inhibits F-VIIa-TF complex and F-Xa (B51). 

The procoagulant factors produced by endothelial cells are the coagulation factors von Willebrand factor (WF), F-V, F-VIII, tissue factor (TF), and plasminogen activator inhibitor (PAI), which blocks the activators u-PA and t-PA and counteracts fibrinolysis (G21, FI6). It has been shown that under the influence of complement activation (C9), in response to endotoxin in vitro (C24), in experimental E. coli sepsis in baboons (D30), and after stimulation with TNF (Al, N6), endothelial cells up-regulate the expression of TF, down-regulate TM and inhibit the production of t-PA and PAF. Thus, the balance may shift in the procoagulant direction with a large excess of PAI-1. 

Protein C and Protein S. PC and PS may inhibit thrombin formation and complex with PAI, thereby promoting fibrinolysis. During sepsis, PC activity is significantly reduced, either by consumption or by TM down-regulation, while increased levels of ClbBP inhibit PS. Infusion of activated PC and PS protected animals from the lethal effect of bacteria. Administration of PC and PS concentrates should be studied carefully in septic patients before their use is recommended (F14). 

Narayanan S. Inhibition of platelet aggregation and release and fibrinolysis. Ann Clin Lab Sci 1989 19,260-5. 

Another theory is that the inhibition of fibrinolysis is due to the interaction of Lp(a) with tPA bound to fibrin, and thereby influencing plasminogen activation (L10, R17, R18). Von Hodenberg (H32), however did not find a relationship between Lp(a) level and treatment success of thrombolysis in acute myocardial infarction with recombinant tPA. 

Plasminogen activator inhibitor-1 (PAI-1) Systemic Haemostatic system Inhibits fibrinolysis... 

Tranexamic acid inhibits fibrinolysis. It is used to prevent bleeding or to treat bleeding problems in various conditions and in the management of... 

The fibrin thrombus resulting from blood clotting (see p. 290) is dissolved again by plasmin, a serine proteinase found in the blood plasma. For this purpose, the precursor plasminogen first has to be proteolyti-cally activated by enzymes from various tissues. This group includes the plasminogen activator from the kidney (urokinase) and tissue plasminogen activator (t-PA) from vascular endothelia. By contrast, the plasma protein a2-antiplasmin, which binds to active plasmin and thereby inactivates it, inhibits fibrinolysis. 

Partially responsible for inhibition of the extrinsic pathway. Inactivates factors V and VIII and promotes fibrinolysis. Activity declines following warfarin administration. cofactor to accelerate the anticoagulant activity of protein C. Decreased levels occur following warfarin administration. ... 

Carboxylic Acid Derivative] Uses Excessive bleeding from systemic hyperfibrinolysis urinary fibrinolysis Action Fibrinolysis via inhibition of TPA substances Dose Adults. 5 g IV or PO (1st h) followed by 1-1.25 g/h IV or... 

Aminocaproic acid and tranexamic acid inhibit fibrinolysis by inhibiting plasminogen binding to fibrin or fibrinogen and the conversion of plasminogen to plasmin. 

In much the same way the number of interventions are possible at the level of fibrinolysis including thrombin-activateable fibrinolysis inhibitor, agents that block factor Xllla or inhibit plasminogen activator inhibitor therapy. 

Sehneider, M., Nesheim, M. (2003). Reversible inhibitors of TAFIa ean both promote and inhibit fibrinolysis. J. Thromb. Haemost, 1, 147-154. 

It inhibits plasmin and kallikrein, thus directly affecting fibrinolysis. It also inhibits the contact phase activation of coagulation which both initiates coagulation and promotes fibrinolysis. 

Both e-aminocaproic acid and tranexamic acid may improve haemostasis by a combination of inhibition of fibrinolysis, reduced release of tPA, and preservation of platelet function. Tranexamic acid is more potent and has the same low toxicity as -aminocaproic acid and the latter is now seldom used and is no longer registered for clinical use in many countries. 

The antithrombotic effects of NO are also mediated by NO-dependent inhibition of platelet aggregation. Both endothelial cells and platelets contain eNOS, which acts to regulate thrombus formation. Thus, endothelial dysfunction and the associated decrease in NO generation may result in abnormal platelet function. As in vascular smooth muscle, cGMP mediates the effect of NO in platelets. NO may have an additional inhibitory effect on blood coagulation by enhancing fibrinolysis via an effect on plasminogen. 

---